| Literature DB >> 35343629 |
Duarte C Barral1, Leopoldo Staiano2,3, Cláudia Guimas Almeida1, Dan F Cutler4, Emily R Eden5, Clare E Futter5, Antony Galione6, André R A Marques1, Diego Luis Medina2,7, Gennaro Napolitano2,7, Carmine Settembre2,8, Otília V Vieira1, Johannes M F G Aerts9, Peace Atakpa-Adaji10, Gemma Bruno2, Antonella Capuozzo2, Elvira De Leonibus2,11, Chiara Di Malta2,7, Cristina Escrevente1, Alessandra Esposito2, Paolo Grumati2, Michael J Hall1, Rita O Teodoro1, Susana S Lopes1, J Paul Luzio12, Jlenia Monfregola2, Sandro Montefusco2, Frances M Platt6, Roman Polishchuck2, Maria De Risi2, Irene Sambri2,7, Chiara Soldati2, Miguel C Seabra1.
Abstract
Since the discovery of lysosomes more than 70 years ago, much has been learned about the functions of these organelles. Lysosomes were regarded as exclusively degradative organelles, but more recent research has shown that they play essential roles in several other cellular functions, such as nutrient sensing, intracellular signalling and metabolism. Methodological advances played a key part in generating our current knowledge about the biology of this multifaceted organelle. In this review, we cover current methods used to analyze lysosome morphology, positioning, motility and function. We highlight the principles behind these methods, the methodological strategies and their advantages and limitations. To extract accurate information and avoid misinterpretations, we discuss the best strategies to identify lysosomes and assess their characteristics and functions. With this review, we aim to stimulate an increase in the quantity and quality of research on lysosomes and further ground-breaking discoveries on an organelle that continues to surprise and excite cell biologists.Entities:
Keywords: TFEB; endolysosomes; lysosomal storage diseases; lysosome biogenesis; lysosome exocytosis; lysosome-related organelles; lysosomes; mTOR; membrane contact sites
Mesh:
Year: 2022 PMID: 35343629 PMCID: PMC9323414 DOI: 10.1111/tra.12839
Source DB: PubMed Journal: Traffic ISSN: 1398-9219 Impact factor: 6.144
FIGURE 1Transmission electron micrographs of electron‐dense lysosomes containing endocytosed gold particles. Primary porcine retinal pigment epithelial cells were incubated with bovine serum albumin (BSA)‐gold for 2 hours, followed by overnight chase to load lysosomes. Gold particles aggregate in the acidic environment of the lysosome after degradation of the BSA. Lysosomes are electron dense and sometimes contain membrane whorls. Scale bar, 200 nm
FIGURE 2Lysosome heterogeneity and the lysosome cycle. Lysosomes accumulate near the nucleus, where they fuse with endosomes, phagosomes or autophagosomes to generate highly acidic degradative organelles (endolysosomes, phagolysosomes or autolysosomes). A process of lysosome reformation then occurs and can involve tubulation and budding to form less acidic protolysosomes, which may require replenishing with lysosomal enzymes. Lysosomes are also found peripherally, where they tend to be smaller and less acidic, and can be stimulated to fuse with the plasma membrane during lysosome exocytosis
Examples of lysosome‐related organelles (LROs)
| Organelle name | Cell type | Organ | Function | Major content(s) | Membrane markers | Regulators of biogenesis | Phenotype when defective | Disease(s) | Refs. |
|---|---|---|---|---|---|---|---|---|---|
| Melanosome | Melanocytes | Skin (and hair) | Pigmentation | Melanin | TYRP‐1, ATP7A, OCA2, MART‐1, DCT | AP‐1, AP‐3, BLOC, Rab32, Rab38 | Hypopigmentation, albinism | Hermansky‐Pudlak syndrome, Chediak‐Higashi syndrome, Griscelli syndrome | [ |
| Weibel‐Palade body | Endothelial cells | Endothelium | Vascular development and homeostasis, haemostasis. | von Willebrand factor (VWF) | P‐selectin, CD63, Rab27a (mature only) | AP‐1, AP‐3, Rab27, MyRIP | Bleeding and multiple vascular dysfunctions | Von Willebrand's Disease, HPS, Griscelli, etc | [ |
| Platelet alpha‐granule | Platelets | Blood | Haemostasis | Many proteins, including VWF, fibrinogen, PF4 and beta‐thromboglobulin | P‐selectin | VPS33B, VPS16, NBEAL2 | Bleeding | von Willebrand's disease, Hermansky‐Pudlak syndrome, Griscelli syndrome, arthrogryposis‐renal dysfunction‐cholestasis syndrome, grey platelet syndrome, Wiskott‐Aldrich, Bernard‐Soulier, Glanzmann thromasthenia syndromes. | [ |
| Platelet dense granule | Platelets | Blood | Haemostasis | Small molecules; including serotonin, ATP/ADP, Ca | MRP4 nucleotide transporter, CD63, LAMP1, LAMP2 | BLOC, AP‐3 | Bleeding | Hermansky‐Pudlak syndrome, Chediak‐Higashi syndrome, Griscelli syndrome | [ |
| Lamellar body | Alveolar type II epithelial cells | Lung | Breathing | Surfactants (SP‐1, SP‐B, SP‐C, SP‐D) | ABCA3, LAMP3 | AP‐3 | Collapse of alveoli, lung fibrosis | Hermansky‐Pudlak syndrome | [ |
| MHC Class II compartment | Antigen‐presenting cells (dendritic cells, B lymphocytes, macrophages, Langerhans cells) | Immune system | Processing of antigenic peptides for presentation: Adaptive immune response | Antigen‐presenting molecules (MHC Class II, HLA‐DM) | LAMP1 | Arl8, Arl14, Arf7, AP‐1, AP‐2. | Immune deficiency | Chediak‐Higashi syndrome | [ |
| Eosinophil secretory (specific) granule | Eosinophils | Bone marrow/blood | Inflammatory, allergic and immunomodulatory responses | MBP, PRG2, ECP, EDN, EPX/O, plus cytokines, chemokines and growth factors | CD63, VAMP7 and 8 | Poorly understood | Asthma | poorly understood | [ |
| Ruffled border/secretory lysosome | Osteoclasts | Bone | Bone remodelling | Cathepsin K | v‐ATPase, OSTM1, Rab7 | Rab7 Rab27; v‐ATPase‐alpha3 | Petrosis/osteoporosis | Griscelli syndrome | [ |
| Azurophilic granule | Neutrophils | Blood | Innate Immunity | Myeloperoxidase, cytokines, chemokine, lysosomal enzymes | CD63 | AP‐3 | Neutropenia | Hermansky‐Pudlak syndrome | [ |
| Acrosome | Sperm | Semen | Fertilization | Acrosin, other hyodrolases | Spaca1 (SAMP32) | Clathrin, CALM, GOPC, ATG7, VPS54/GARP, GM130 | Infertility, globozoospermia | Not defined | [ |
| Fusiform vesicle | Facet AKA Umbrella cells | Urothelium | Expansion‐contraction cycle of urothelium | Uroplakins | Rab27b | VPS33A/HOPS complex, Rab8, Slac2‐a, Slp2‐a, Vamp8 | Loss of FVs, accumulation of multivesicular bodies | Hermansky‐Pudlak syndrome | [ |
| Notochord vacuole | Notochord inner cells | Notochord | Formation of intervertebral discs | Liquid providing hydrostatic force | LAMP1 | Rab32a | Scoliosis | Hermansky‐Pudlak syndrome | [ |
| Cytolytic granule | NK cells, CTLs | Immune system | Elimination of virally‐infected or oncogenic target cells | Perforin, lytic enzymes (eg granzyme) | LAMP1, CD63 | Immune deficiency, viral infections | Griscelli syndrome | [ |
FIGURE 3Dextran assay. Representative high content images obtained with Opera (40x water objective) of (A) uptake kinetics (from 5 to 20 minutes) in HAP‐1 cells (cell line derived from chronic myelogenous leukaemia) loaded with Alexa Fluor 568‐dextran (Thermo Fisher, D22912) (in red) and (B) uptake kinetics (from 30 minutes to 3 hours) in mouse embryonic fibroblasts (MEF). Nuclei stained with Hoechst are shown in blue. Scale bar, 20 μm
FIGURE 4DQ‐BSA assay. Representative high content images of DQ‐BSA puncta in ARPE‐19 human retinal pigment epithelial cells treated with DMSO or Torin‐1 (1 μM for 3 hours) and incubated for 16 hours with 10 μg/mL of DQ‐BSA. Lower row images show the same cells subjected to analysis for the selection of DQ‐BSA puncta (selected spots traced in green; discarded spots with very low fluorescent intensity traced in red). More details in Data S1. Scale bar, 20 μm
Electron microscopy methods for analysis of lysosomes
| Approach | Description | Pros | Cons | Refs. |
|---|---|---|---|---|
| Morphology: Conventional TEM ± high pressure freezing (HPF) | Lysosomes appear as relatively electron dense organelles between 200 and 600 nm in diameter often containing multilamellar whorls by conventional TEM |
Conventional TEM is relatively straightforward for any lab with EM facilities. HPF‐TEM reduces fixation artefacts for improved ultrastructure. | May sometimes be difficult to distinguish from other organelles, eg, autophagosomes. HPF requires specialist equipment and expertize. | [ |
| Internalized probes | Pulse/chase experiments using probes labelled with gold particles or HRP can help identify endocytic organelles. Aggregated gold indicates lysosomal delivery as the protein component that stabilizes the gold is degraded and the gold aggregates in the low pH of the lysosome. | Labels endocytic organelles without the need for immuno‐EM. Pulse/chase experiments with different sized gold particles (or gold and HRP‐labelled probes) allow different endosomal populations and kinetics of lysosomal delivery to be studied. | Can use large amounts of antibody or ligand. Can only be used to trace the endocytic pathway to the lysosome (not Golgi to lysosome traffic). | [ |
| Pre‐embedding labelling immuno‐EM | Cells are stained with antibodies specific for lysosomal markers as for IF, but the secondary antibody is conjugated to nanogold rather than fluorescent label. Cells are then prepared for conventional EM, but with an additional nanogold enhancement step. | This is an accessible immuno‐EM technique. Any lab can do the labelling; this immune‐EM approach is therefore available to any lab with access to conventional EM facilities. | Permeabilization can compromise morphology and conditions to retain morphology may not be sufficient to access luminal proteins, so only suitable for labelling the cytosolic domain of lysosomal proteins. Only one protein can be labelled at a time because of variability of the enhanced nanogold size. | [ |
| Cryo‐Immuno EM (Tokuyasu method) | Cells fixed in PFA ± low levels of glutaraldehyde and embedded in gelatine are frozen in liquid nitrogen. Ultrathin frozen sections are labelled with antibodies to lysosomal markers at room temperature with up to three antibodies and protein‐A‐gold/gold‐conjugated secondary antibodies of different gold sizes. | Eliminates the possibility of artefacts associated with dehydration and the requirement for permeabilization. Up to three proteins can be labelled at once. | A level of technical skill and specialist equipment is required for ultrathin cryo‐sectioning. | [ |
| 3D‐EM |
Electron tomography (ET): 3D reconstructions are generated from a tilt series through a thicker section. |
3D‐ET: High resolution imaging and tomography‐compatible TEM is the only specialist equipment required. Can be coupled with HPF or cryo‐EM for close to native state preservation. |
3D‐ET: Relatively small sample depths can be imaged. High volume of data to be processed and stored. | [ |
|
Serial block‐face scanning EM (SBF‐SEM): automated serial sectioning with newly exposed surfaces imaged by integrated SEM. Focused‐ion beam scanning EM (FIB‐SEM): Serial milling with a focused beam of high‐energy gallium ions, block‐face imaged by SEM. |
SBF‐SEM and FIB‐SEM: Can image through large volumes. Cryo‐FIB‐SEM removes any fixation artefacts. |
SBF‐SEM and FIB‐SEM: Expensive specialist equipment is required. Imaging internalized gold‐labelled probes is stretching the resolution. Datasets can be very large. | ||
|
Array tomography/automated tape‐collecting ultramicrotome SEM (ATUM‐SEM): Serial sections are collected on a slide or tape for SEM imaging. |
Array tomography/ ATUM‐SEM: Non‐destructive method, sections are kept on slides for future use. |
Array tomography/ATUM‐SEM: Requires manual serial sectioning. | ||
| CLEM | Information on lysosomal protein expression and dynamics gained from light microscopy is correlated with EM images. | Dynamic events and localization of fluorescent proteins or probes imaged by light microscopy can be correlated with cellular ultrastructure at EM resolutions. | Technically challenging and time consuming. | [ |
FIGURE 5Transmission electron micrographs showing lysosome membrane contact sites (MCS). (A) Lysosome:ER MCS in HeLa cells. (B) Lysosome: mitochondria MCS in HeLa cells incubated with horseradish peroxidase for 6 hours prior to incubation with DAB and preparation for EM. Orange arrows, MCS. Scale bars, 200 nm
Lysosomal calcium modulating agents that selectively release endolysosomal calcium and can be paired with cytosolic calcium indicators for an indirect assessment of lysosomal calcium
| Drug | Mechanism of action | Practical considerations | Refs. |
|---|---|---|---|
| Glycyl‐ | Peptidase‐dependent lysosomal permeabilization | Appropriate controls are required to check for the pH‐dependent (cathepsin C independent) effects of GPN | [ |
| Bafilomycin A1/Concanamycin A | v‐ATPase inhibitor | Slow acting as effect depends on H+ and Ca2+ leak from lysosomes. Effects can be lacking in cells with a minimal lysosomal Ca2+ ‘leak’ | [ |
| Nigericin | K+/H+ exchanger (Ionophore) | Indirect effect on lysosomal Ca2+. Poor selectivity to lysosomes | [ |
| Monensin | Na+/H+ exchanger (Ionophore) | ||
| NAADP | TPC‐mediated Ca2+ release |
NAADP is cell impermeant. Usually microinjected. Esterified form, NAADP‐AM, not easily accessible commercially and sometimes unstable on storage | [ |
| ML‐SA1 | TRPML1‐mediated Ca2+ release | ML‐SA1 can evoke complex global Ca2+ signals in some cells, therefore effective controls are required to elucidate lysosomal contributions | [ |
| Sphingosine | TPC1‐dependent lysosomal Ca2+ release | Caged sphingosine utilized but not commercially available. | [ |
| TPC2A1(N) | TPC2‐dependent lysosomal Ca2+ release | Direct activator of TPC2, mimics NAADP | [ |
| TPC2A1(P) | TPC2‐dependent lysosomal cation fluxes | Direct activator of TPC2, mimics PI(3,5)P2 promotes sodium fluxes and smaller Ca2+ fluxes | [ |
Ca2+ indicators for measuring juxta‐ and intra‐lysosomal calcium
| Ca2+ indicator | Localization |
| Refs. |
|---|---|---|---|
| LAMP1‐YCaM | Juxta‐lysosomal | 250 nM | [ |
| GCaMP3‐TRPML1 | Juxta‐lysosomal | 660 nM | [ |
| LAMP1‐GGECO1.2 | Juxta‐lysosomal | 1.2 μM | [ |
| TPC2‐GGECO1.2 | Juxta‐lysosomal | 1 μM | [ |
| Fura‐2 dextran (fura‐dextran dye) | Intra‐lysosomal | 200 μM | [ |
| Cathepsin D‐Aequorin | Intra‐lysosomal | 260 μM | [ |
| Oregon green BAPTA‐1 dextran | Intra‐lysosomal | 500 μM | [ |
| Rhod dextran (low affinity) | Intra‐lysosomal | 690 μM | [ |
| CalipHluor | Intra‐lysosomal |
| [ |
Affinity for Ca2+ not measured in situ.
List of TFEB target genes involved in lysosome biogenesis and autophagy whose expression can be monitored by quantitative PCR
| Gene name | Protein name |
|---|---|
|
| Transmembrane glycoprotein NMB |
|
| Ras‐related GTP‐binding protein D |
|
| Ras‐related GTP‐binding protein C |
|
| Folliculin |
|
| Folliculin‐interacting protein 1 |
|
| Lysosome‐associated membrane glycoprotein 1 |
|
| Sequestosome‐1 |
|
| UV radiation resistance‐associated gene protein |
|
| WD repeat domain phosphoinositide‐interacting protein 1 |
|
| Peroxisome proliferator‐activated receptor gamma coactivator 1‐alpha |
|
| V‐type proton ATPase subunit d 1 |
|
| V‐type proton ATPase subunit d 2 |
|
| V‐type proton ATPase subunit H |
|
| Cathepsin D |
|
| Cathepsin F |
|
| Mucolipin‐1 |
FIGURE 6Globotriaosylceramide (Gb3) accumulation in HeLa cells knockout (KO) for α‐galactosidase, treated with 1‐phenyl‐2‐decanoylamino‐3‐morpholino‐1‐propanol (PDMP). Gb3 lipid accumulation in GLA KO Hela cells treated with PDMP (glucosylceramide synthase inhibitor) or DMSO, as a control. This read‐out has been used to develop a Gb3 lipid accumulation assay. PDMP was used as a positive control for Shiga toxin (STX). ***P ≤ .0001, as determined by Student's t‐test. Scale bar, 20 μm
FIGURE 7Lysosomal morphometric assay. Results were obtained by the quantitative high content image analysis of normal ARPE‐19 human retinal pigment epithelial cells (WT) and ARPE‐19 Niemann‐Pick C (NPC) 1 KO cells generated by genome editing, as a model of NPC1, a lysosomal storage disease in which lysosomes accumulate cholesterol. The increase in the number of lysosomes and the percentage of cells showing lysosomal aggregation was quantified in NPC1 KO cells and compared to WT cells. Scale bar, 20 μm
FIGURE 8Intracellular galectin 3 (GAL3) accumulation upon treatment with LLOMe. Human ARPE‐19 retinal pigment epithelial cells were stained for GAL3 using a specific antibody (green). Untreated cells show no GAL3 puncta, whereas after 30 minutes of treatment with LLOMe (a potent inducer of lysosome membrane permeabilization), the number of GAL3 spots increase, indicating accumulation. Washout reverts the GAL3 accumulation. The graphs show the number of GAL3 spots per cell. Scale bar, 20 μm
FIGURE 9Lysosomal permeabilization assay. In control conditions (CTRL), Acridine Orange stains lysosomes (red puncta), while the treatment with concanamycin A (Conc. A, a specific inhibitor of v‐ATPase activity; 100 nM, 1 hour) dramatically reduces lysosomal staining. With the change in lysosomal pH, there is also an increase in green intensity. The plots show the number of red spots per cell, and the intensity ratio between red and green emission. The assay is developed with live cells and in order to perform a high content analysis, a stable HeLa cell clone expressing the histone protein H2B fused with cyan fluorescent protein (CFP; blue) to detect the nuclei (n = 500 cells per condition) is used. Scale bar, 20 μm
Chromophores and fluorophores commonly used in artificial substrates for lysosomal hydrolases
| Category | Compound |
|---|---|
| Chromophores | 4‐nitrophenol (4‐NP) |
| 4‐nitrocatechol (4‐NC) | |
| 2‐naphthol (2‐NP) | |
| p‐nitroanilide | |
| 5‐bromo‐4‐chloro‐3‐hydroxyindole | |
| Fluorophores | 4‐methylumbelliferyl (4‐MU) |
| 7‐amino‐4‐methylcoumarin (AMC) | |
| 7‐hydroxy‐9 | |
| 7‐methoxycoumarin‐4‐yl)acetyl (MCA) / 2,4‐dinitrophenyl (Dnp) | |
| Lucifer yellow/4‐(4‐Dimethylaminophenylazo)benzenesulfonyl) (Dabsyl) | |
|
Fluorescein Resofurin | |
| ELF 97 | |
| Cresyl violet | |
| Nitrobenzoxadiazole (NBD) |